Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges. - Wikidata - wikimedia - TriplyDB

Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.

Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.

http://www.wikidata.org/entity/Q37984189

about

From bench to bedside: immunotherapy for prostate cancer Current treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasis Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors.Human prostatic acid phosphatase: structure, function and regulation.Skeletal metastasis: treatments, mouse models, and the Wnt signaling.Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis.Immunotherapy for prostate cancer enters its golden age.Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer.Risk factors for metastatic prostate cancer: A sentinel event case series.Sipuleucel-T (Provenge(®))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention.

P2860

Q26864390-765AA150-CD94-44A9-ABB3-A7B3CA24856C Q34448130-DAE56695-7E57-42DA-B237-F5D93EFE6B86 Q36690209-A9428885-FEBF-49EC-BB8A-0047D04E42E5 Q36913762-04E3F857-8556-4E44-98B3-78303F0148B8 Q37354085-4EE976EA-7B64-43A0-A240-6C2B6C8B197C Q37531813-25625A03-AB74-40C8-932C-7AAB5D5B9715 Q39577914-878B6C56-7811-42A7-8EFB-C4FC4979AE31 Q41573500-39791D97-00AC-4CA3-87E0-478CD02A87B4 Q47821557-8F79ABFA-481A-4AD9-8832-EF38F0CC1DB2 Q53518864-16BCBFE7-3EB0-4B5C-A113-28EB63B7A340

P2860

Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.

http://www.wikidata.org/entity/Q37984189

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.

@en

Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.

@nl

type

label

Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.

@en

Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.

@nl

prefLabel

Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.

@en

Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.

@nl

P1433

Q37984189-EC31ABAF-97C3-42F1-9D6C-CCDBC7EFCD68

P1476

Q37984189-69B834FC-CD44-4E88-B593-C7849859FC93

P2093

Q37984189-B0DD38BD-87BE-4773-9C45-87C429113083

P2860

Q37984189-118D48C8-97CD-491C-A279-C80334EF6C1C

Q37984189-139D1EDE-0045-48C7-A1D3-E2C03F1003E1

Q37984189-173E1EA6-9B11-404C-A731-1C746AD12E20

Q37984189-1ED24B4D-A426-4920-91AE-B5DB768561AB

Q37984189-260C16D6-7AE9-4CC7-8BDF-C2DF85BF6A8F

Q37984189-26ABCDE9-80FC-4698-81BA-AC7B68C23A71

Q37984189-32F2E1D5-2DFD-4D7E-8A79-AB2E91ADE384

Q37984189-36BF8DCA-897B-499F-98CB-950DA9A5208E

Q37984189-467C393E-0548-4E9E-BDAB-1A9E44F15B6F

Q37984189-52292A19-78A2-4FEB-986C-52EA48244394

P304

Q37984189-4F0D56C5-ED0E-46F9-98F4-C72A3E978C45

P31

Q37984189-2AD50CD0-2300-4782-9159-3CEBA5ABC784

P356

Q37984189-2EE4D473-D545-450C-BC3A-E10003D3295E

P433

Q37984189-882BD349-AE81-41E1-B2EC-243E10FE02A5

P478

Q37984189-2C300347-2DF4-420B-A0D8-BDC97B65C4A4

P50

Q37984189-A10D8361-46C1-4A24-A46C-5964A2BAEE72

P577

Q37984189-604D2451-C6DC-4CA8-84EC-60D2441261FF

P5875

Q37984189-C6F2191F-FC87-4FB5-B7E2-A8CA8C41D7F9

P698

Q37984189-EABBDBEB-A872-4F39-AC59-17491008A136

P356

P1433

Human Vaccines & Immunotherapeutics

P1476

Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges

@en

P2093

Channing J Paller

http://www.w3.org/2001/XMLSchema#string

P2860

Improved endpoints for cancer immunotherapy trials

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer

Cancer statistics, 2010

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Abiraterone and increased survival in metastatic prostate cancer

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

P304

509-519

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/HV.18860

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Emmanuel S Antonarakis

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221834682

http://www.w3.org/2001/XMLSchema#string

P698

22336881

http://www.w3.org/2001/XMLSchema#string